Data-Powered Decision-Making in Personalized Medicine: Increasing the Frequency of Patient Engagement | Diaceutics

Data-Powered Decision-Making in Personalized Medicine: Increasing the Frequency of Patient Engagement

July 22nd, 2013

Sanna Jousi

In this Expert Insight, Sanna Jousi of Diaceutics discusses patients’ perceptions of the pharmaceutical industry and diagnostic testing and the opportunity this presents for the pharma and the diagnostic industries to connect with patients.

A recent survey illustrated the perception of consumers towards the pharmaceutical industry. We will not go into the details again as you can read more here. However, this survey and others prompted us (wearing our personalized medicine hats, of course) to consider how companion diagnostics might change the nature of pharma/patient involvement. To do this, we set out using social media, to contrast the attitudes patients had about Zelboraf during a four-week period after its launch, versus another non-targeted oncology therapy during the same period shortly after its launch.

Both therapies carried the same positive reaction in about 14 per cent of patients, but a negative reaction was observed in 50 per cent of patients commenting on the non-targeted therapy versus only 17 per cent in patients commenting on Zelboraf. Only 36 per cent of consumers were neutral-factual in their comments about the non-targeted therapy versus 70 per cent in Zelboraf.

We surmised this was too small a sample despite the perceptual differences in targeted versus non-targeted therapies and, as a result, we do not wish to extrapolate too much from these data points at this stage. A more extensive patient engagement initiative is underway and we will report back on that in due course.

However, as we probed around different levels of consumer engagement on social media regarding health care, we did spot something most compelling. Patients talk about diagnostics and testing four times more frequently than they talk about treatment. We have repeated this analysis several times over the past 18 months and always see the same thing. Patient activity begins not with a discussion of the right therapy, but the right test. This presents an enormous opportunity for pharma and diagnostic leaders in personalized medicine to interact with patients to discuss their testing choices. We cannot guarantee it will singlehandedly reverse the negative perception consumers have of pharma, but we do conjecture that the concept of targeted therapy and targeted companion testing opens up new opportunities to change the narrative.

Blogs

View all blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications
Facebook
Twitter
YouTube
LinkedIn